KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Other Non-Current Assets (2016 - 2025)

Emergent BioSolutions' Other Non-Current Assets history spans 15 years, with the latest figure at $3.7 million for Q4 2025.

  • For Q4 2025, Other Non-Current Assets fell 80.42% year-over-year to $3.7 million; the TTM value through Dec 2025 reached $3.7 million, down 80.42%, while the annual FY2025 figure was $3.7 million, 80.42% down from the prior year.
  • Other Non-Current Assets reached $3.7 million in Q4 2025 per EBS's latest filing, down from $6.3 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $111.4 million in Q1 2021 to a low of $500000.0 in Q1 2024.
  • Average Other Non-Current Assets over 4 years is $38.7 million, with a median of $18.9 million recorded in 2024.
  • The largest YoY upside for Other Non-Current Assets was 1120.0% in 2025 against a maximum downside of 80.42% in 2025.
  • A 4-year view of Other Non-Current Assets shows it stood at $58.2 million in 2021, then fell by 29.9% to $40.8 million in 2022, then plummeted by 53.68% to $18.9 million in 2024, then plummeted by 80.42% to $3.7 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's Other Non-Current Assets are $3.7 million (Q4 2025), $6.3 million (Q3 2025), and $6.1 million (Q2 2025).